This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Antibody deficiency with near-normal immunoglobulins / Specific Antibody Deficiency거의 정상의 면역글로불린 또는 고면역글로불린혈증을 동반한 항체결핍

ICD-10: D80.6 | Synonyms: Antibody deficiency with near-normal immunoglobulins, Specific antibody deficiency (SAD)

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Background to the establishment of the concept

In the 1970s–1980s, as patients whose total serum immunoglobulin levels were normal but who failed to respond to vaccination were found in clinical practice, interest in abnormalities of antibody function increased. Traditionally, immunodeficiency was defined by a decrease in total immunoglobulin, but it was recognized that functional antibody responses to specific antigens may be lacking even when immunoglobulin levels are normal or elevated.

Introduction of the concept of specific antibody deficiency (SAD)

When Sorensen and Polmar (1984) and Ambrosino et al. (1988) described a group of patients who failed to respond to pneumococcal polysaccharide vaccine despite normal serum immunoglobulins, the concept of "Specific Antibody Deficiency (SAD)" was established. This concept shows that functional responsiveness, not the total amount of antibody, is the core of immune defense.

Classification by European and American immunology societies

The European Society for Immunodeficiencies (ESID) and the Immune Deficiency Foundation (IDF) in the US define ICD-10 D80.6 as a category that includes IgG subclass deficiency, specific antibody deficiency, and some antibody deficiencies with hyperimmunoglobulinemia.

Status in Korea

In Korea, independent epidemiological data on specific antibody deficiency are lacking, and it is diagnosed sporadically, mainly in the course of evaluating recurrent respiratory infections or immunodeficiency. Diagnoses have been increasing since the 2010s, when pneumococcal polysaccharide vaccine response testing began to be used clinically.

2. Causes

Causes of specific antibody deficiency (SAD)

Specific antibody deficiency is caused by a defect in the B-cell response to T-cell-independent polysaccharide antigens or a defect in the response to T-cell-dependent protein-conjugated antigens. In particular, a selective defect in the IgG response to pneumococcal capsular polysaccharide antigens is characteristic.

IgG subclass deficiency

The IgG2 subclass is mainly involved in antibody responses to polysaccharide antigens, and IgG2 deficiency is closely associated with specific antibody deficiency. IgG1 and IgG3 deficiencies are also associated with reduced responses to protein antigens.

Antibody deficiency with hyperimmunoglobulinemia

This refers to cases in which total IgG or IgM is elevated but specific antibody production is deficient, caused by overproduction of nonfunctional antibodies. Differentiation from secondary causes such as HIV infection and EBV infection is necessary.

Secondary causes

Post-splenectomy status, functional asplenia such as in sickle cell anemia, immunosuppression after organ transplantation, and steroid therapy can secondarily cause deficient antibody function.

3. Genetics

Genetic background of IgG subclass deficiency

The genes encoding IgG subclasses are in the immunoglobulin heavy chain constant region gene cluster (IGHG1–IGHG4) located at 14q32.33. Some IgG subclass deficiencies are reported to be due to deletions of these genes. Deletion of the IGHG2 gene can cause IgG2 deficiency.

Polygenic genetic predisposition

Most specific antibody deficiency has a polygenic predisposition, with polymorphisms in immune regulatory genes contributing in combination rather than a single-gene defect. TACI (TNFRSF13B) and BAFF-R variants are found in some patients.

Familial occurrence

Most cases are sporadic, but familial clustering is rarely reported. Related antibody immunodeficiencies such as selective IgA deficiency and CVID are sometimes present in siblings or parents.

4. General epidemiology

Prevalence estimates

Specific antibody deficiency (SAD) is estimated to be one of the most commonly found primary immunodeficiencies in the immunodeficiency evaluation of children with recurrent infections. Some studies report that SAD is found in 10–20% of children with recurrent otitis media or sinusitis.

Characteristics by age

It is most often diagnosed in children, especially at 2–5 years of age. Because responses to polysaccharide antigens are immature in young children, differentiation from physiological "immaturity of the antibody response" is important (in general, polysaccharide vaccine responses are not mature at 2 years of age or younger).

Sex distribution

No major difference between males and females is reported. Some studies have reported a slight male predominance of IgG2 deficiency-related SAD in children.

Status in Korea

In Korea, SAD is increasingly recognized in the field of pediatric immunology and allergy, which evaluates children with recurrent respiratory infections. Diagnoses have been increasing since the 2010s, when pneumococcal polysaccharide vaccine response testing began to be used clinically.

5. Pathophysiology

Defective B-cell response to polysaccharide antigens

Polysaccharide antigens stimulate B cells in a T-cell-independent manner, mainly inducing IgM and IgG2 antibodies. Splenic marginal zone B cells play a key role in this response. Immaturity, deficiency, or dysfunction of splenic marginal zone B cells has been proposed as a major pathogenesis of specific antibody deficiency.

The special role of IgG2

IgG2 is the predominant isotype in antibody responses to polysaccharides. In patients with IgG2 deficiency, opsonization responses to encapsulated bacteria such as pneumococcus and Haemophilus influenzae are reduced, and the risk of invasive infection increases.

Mechanisms in hyperimmunoglobulinemia

This refers to cases in which total IgG is elevated but specific antibody function is deficient, with nonspecific or autoreactive antibodies making up the majority while pathogen-specific antibodies are not produced. Chronic immune stimulation (chronic infection, autoimmune disease) can cause this condition.

6. Symptoms

Recurrent respiratory infections

The most common symptoms are recurrent otitis media, sinusitis, pneumonia, and bronchitis. In children, 4 or more episodes of otitis media per year, 2 or more episodes of pneumonia, or chronic sinusitis (lasting 3 months or longer) are characteristic.

Invasive bacterial infections

Bacteremia, meningitis, and pneumonia caused by pneumococcus and Haemophilus influenzae occur rarely. Reduced opsonization responses to encapsulated bacteria increase the risk of invasive infection.

Natural course

In children, as the immune system matures with age, specific antibody responses improve and symptoms often improve. In some, symptoms persist or worsen into adulthood, and in these cases there is also a possibility of transition to CVID.

Spectrum of mild symptoms

The severity of symptoms is highly variable, showing a broad spectrum from mild recurrent upper respiratory infections to severe invasive infections.

7. Signs

Physical examination findings

Chronic otorrhea (ear discharge), nasal polyps, and sinus tenderness due to recurrent infections may be observed. In some patients who develop bronchiectasis, wheezing and abnormal breath sounds may be heard on auscultation.

Serum immunoglobulin findings

Serum IgG, IgA, and IgM are within the normal range, or in some patients hyperimmunoglobulinemia (elevated total IgG or IgM) is observed. IgG subclass testing may reveal decreased IgG2 or IgG4.

Specific antibody response testing

If, 4–6 weeks after pneumococcal polysaccharide vaccine (PPSV23) vaccination, the serum antibody response increases less than 2-fold or fails to reach protective titers (>1.3 μg/mL per serotype), SAD is strongly suggested. A normal response is defined as a 4-fold or greater antibody increase or achievement of protective titers for 70% or more of the vaccine serotypes.

8. Screening

Evaluation sequence for patients with recurrent infections

In patients with recurrent infections whose quantitative serum immunoglobulin (IgG, IgA, IgM) tests are normal, IgG subclass (IgG1–IgG4) testing is performed. If IgG subclasses are also normal or borderline, SAD is evaluated by specific antibody response testing before and after pneumococcal polysaccharide vaccination.

Age considerations

In children under 2 years of age, responses to polysaccharide antigens are physiologically insufficient, so caution is needed in diagnosing SAD. At this age, evaluation by the response to protein-conjugated pneumococcal vaccine (PCV) is more appropriate.

Follow-up testing

Because it may be difficult to draw a conclusion from a single test, retesting after 3–6 months is used to assess the persistence of the response and changes in immune function.

9. Diagnosis

Diagnostic criteria for SAD

① Serum IgG, IgA, and IgM normal or elevated ② Insufficient specific antibody response after pneumococcal polysaccharide vaccine (PPSV23) vaccination (failure to reach protective titers or less than 4-fold increase in 50–70% or more of the target serotypes) ③ Exclusion of secondary causes

Diagnosis of IgG subclass deficiency

IgG subclass deficiency is diagnosed when quantitative serum IgG subclass testing (IgG1–IgG4) confirms levels below the age-specific lower limit of normal on 2 or more occasions. IgG2 deficiency is the most clinically significant.

Differential diagnosis

Differential diagnoses include ① CVID (low IgG + low IgA + poor antibody response) ② selective IgA deficiency ③ XLA ④ secondary antibody deficiency (immunosuppressants, protein loss, splenic dysfunction) ⑤ physiological antibody immaturity (children).

10. Treatment

Enhanced vaccination

Appropriate vaccination with pneumococcal conjugate vaccine (PCV13/PCV15) and polysaccharide vaccine (PPSV23), as well as Hib vaccine, meningococcal vaccine, and influenza vaccine, is recommended.

Prophylactic antibiotics

When recurrent infections are severe, low-dose prophylactic antibiotics (amoxicillin, azithromycin) are given for 3–6 months and their effect is evaluated.

Immunoglobulin replacement therapy

Indications for IVIG or SCIG therapy in SAD and IgG subclass deficiency are applied strictly. IVIG is considered in severe recurrent infections, development of bronchiectasis, or failure of prophylactic antibiotics. Because many children improve with maturation, reassessment of when to stop treatment is necessary.

Follow-up

Regular follow-up of serum IgG subclasses, reassessment of immune function, and pulmonary function tests (monitoring for bronchiectasis) are recommended.

11. Prognosis

Natural course in children

In many pediatric patients, specific antibody responses improve with increasing age and symptoms tend to improve spontaneously. Regular follow-up has reported cases in which immunoglobulin levels and antibody responses normalize after adolescence.

Transition to adulthood

In some, the deficiency persists into adulthood, and rarely it progresses to CVID. When recurrent infections persist over a long period, bronchiectasis may develop, which can cause permanent damage to lung function.

Overall prognosis

With appropriate management, most patients can maintain a good quality of life. Diagnosing the condition and starting preventive treatment before bronchiectasis or chronic lung disease develops is key to improving the prognosis.

12. Prevention

Optimizing vaccination

Early vaccination with protein-conjugated vaccines (PCV) against encapsulated bacteria can induce protective antibodies through T-cell-dependent responses. Influenza vaccine is given every year.

Early treatment of recurrent infections

Prompt antibiotic treatment when infection occurs prevents progression to lower respiratory tract infection and bronchiectasis.

Patient education

Patients are educated on early recognition of abnormal infection symptoms, ways to minimize exposure to infection-prone environments (daycare centers, group living facilities), and the importance of hand hygiene. Patients and caregivers are informed of the importance of regular follow-up testing of immune function.

13. References

  1. Ambrosino DM, Umetsu DT, Siber GR, et al. Selective defect in the antibody response to Haemophilus influenzae type b in children with recurrent infections and normal serum antibody levels. J Allergy Clin Immunol. 1988;81(6):1175-1179.
  2. Sorensen RU, Polmar SH. Specific antibody deficiency with normal immunoglobulin concentrations in children with recurrent infections. Pediatr Res. 1984;18(suppl):16A.
  3. Boyle RJ, Le C, Balloch A, et al. The clinical syndrome of specific antibody deficiency in children. Clin Exp Immunol. 2006;146(3):486-492.
  4. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report. J Allergy Clin Immunol. 2012;130(3 Suppl):S1-24.
  5. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.
  6. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S3-23.
  7. Shackelford PG, Granoff DM, Madassery JV, et al. Clinical and immunologic characteristics of healthy children with subnormal serum concentrations of IgG2. Pediatr Res. 1990;27(1):16-21.
  8. Sanders LA, Feldman RG, Voorhorst-Ogink MM, et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun. 1995;63(1):73-81.
  9. van der Pol P, Rabelink T, de Graaff B, et al. IgG2 deficiency: a major risk factor for pneumococcal infection. Infect Immun. 2002;70(2):851-858.
  10. Driessen G, van der Burg M. Educational paper: primary antibody deficiencies. Eur J Pediatr. 2011;170(6):693-702.
  11. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22(3):396-414.
  12. Korean Academy of Pediatric Allergy and Respiratory Disease. Clinical practice guidelines for pediatric immunodeficiency diseases. Seoul: Korean Academy of Medical Sciences; 2021.